Form 8-K - Current report:
SEC Accession No. 0001193125-24-154729
Filing Date
2024-06-05
Accepted
2024-06-05 08:00:32
Documents
14
Period of Report
2024-06-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d838051d8k.htm   iXBRL 8-K 24342
2 EX-10.1 d838051dex101.htm EX-10.1 9466
  Complete submission text file 0001193125-24-154729.txt   163194

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA coya-20240604.xsd EX-101.SCH 2876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE coya-20240604_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE coya-20240604_pre.xml EX-101.PRE 11724
17 EXTRACTED XBRL INSTANCE DOCUMENT d838051d8k_htm.xml XML 3768
Mailing Address 12645 MEMORIAL DR., SUITE F1 #305 HOUSTON TX 77024
Business Address 12645 MEMORIAL DR., SUITE F1 #305 HOUSTON TX 77024 650.739.3939
Coya Therapeutics, Inc. (Filer) CIK: 0001835022 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41583 | Film No.: 241020788
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)